Clinical Trial Update: A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.

View source ↗

Summary

AstraZeneca-sponsored, multicenter retrospective chart review evaluating the potential clinical benefits of retreating EGFR-mutated non-small cell lung cancer p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced or Metastatic EGFR Mutated NSCLC. | Status: COMPLETED